1 results match your criteria: "Clinilabs Sleep Disorder Institute[Affiliation]"
The effects of ramelteon in a first-night model of transient insomnia.
Sleep Med
January 2009
Clinilabs Sleep Disorder Institute, 423 West 55th Street, New York, NY 10019, USA.
Objective: To evaluate the efficacy and safety of ramelteon, a highly selective MT(1)/MT(2) melatonin receptor agonist, for the treatment of transient insomnia in adults.
Methods: In a randomized, double-blind, placebo-controlled, multi-center study, 289 adults naive to a sleep laboratory environment were randomized to receive a single nighttime dose of ramelteon 8 mg, 16 mg, or placebo. The primary variable was latency to persistent sleep measured by polysomnography.